Claimed effect · Tirzepatide

Does Tirzepatide help with cardiovascular events?

A
Grade A — established in humans1 large outcomes RCT (n=13,165) · effect size: small
Short answerEstablished in humans. 1 large outcomes RCT (n=13,165) point the same way: a small effect. SURPASS-CVOT, now published: tirzepatide was non-inferior to dulaglutide on major adverse cardiovascular events in type 2 diabetes. Superiority over an active GLP-1 comparator was not shown, and there is no placebo-controlled cardiovascular outcome trial. On this trial the FDA approved a cardiovascular risk-reduction indication on 28 August 2026; the grade and effect size do not change with the label.

What the studies show

SURPASS-CVOT, now published: tirzepatide was non-inferior to dulaglutide on major adverse cardiovascular events in type 2 diabetes. Superiority over an active GLP-1 comparator was not shown, and there is no placebo-controlled cardiovascular outcome trial. On this trial the FDA approved a cardiovascular risk-reduction indication on 28 August 2026; the grade and effect size do not change with the label.

“A primary end-point event occurred in 801 patients (12.2%) in the tirzepatide group and 862 (13.1%) in the dulaglutide group (hazard ratio, 0.92; 95.3% confidence interval, 0.83 to 1.01; P = 0.003 for noninferiority; P = 0.09 for superiority).”

Verbatim, from the abstractNicholls SJ, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med, 2025

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1
    Nicholls SJ, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT).N Engl J Med, 202513,165 analysed; non-inferior to dulaglutide, superiority not shown.
  2. 2
    Eli Lilly. FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes.Press release, 28 Aug 2026Indication based on SURPASS-CVOT (13,299 randomised; hazard ratio 0.92, 95.3% CI 0.83–1.01 vs dulaglutide).

In context

Tirzepatide is a once-weekly peptide that activates both GIP and GLP-1 receptors. It is approved for type 2 diabetes, weight management and obstructive sleep apnoea, and since August 2026 in the US to lower the risk of major cardiovascular events in adults with type 2 diabetes at high risk. In the only direct head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks) with a similar side-effect profile. It is a prescription medicine; versions sold outside that channel are unlicensed.

Tirzepatide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Tirzepatide proven to help with cardiovascular events?
Yes, as far as human trials can show it: 1 large outcomes RCT (n=13,165). LYO grades this outcome A.
What studies are behind the grade?
SURPASS-CVOT, now published: tirzepatide was non-inferior to dulaglutide on major adverse cardiovascular events in type 2 diabetes. Superiority over an active GLP-1 comparator was not shown, and there is no placebo-controlled cardiovascular outcome trial. On this trial the FDA approved a cardiovascular risk-reduction indication on 28 August 2026; the grade and effect size do not change with the label.
Is Tirzepatide approved for this?
Tirzepatide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Tirzepatide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →